Prognostic value of TROP2 in human nasopharyngeal carcinoma

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 10995-11004

  Guan, Guo Fang ^a   Zhang, De Jun ^a   Wen, Lian Ji ^a   Yu, Duo Jiao ^a   Zhao, Yan ^a   Zhu, Lin ^a   Guo, Ying Yuan ^a   Zheng, Ying ^b  

^a THE SECOND HOSPITAL OF JILIN UNIVERSITY   (China)

^b Tumor Hospital of Jilin Province   (China)

Author keywords

Clinical outcome; EBV; Nasopharyngeal carcinoma; Prognostic predictor; TROP2

Indexed keywords

CELL ADHESION MOLECULE; KI 67 ANTIGEN; SMALL INTERFERING RNA; TACSTD2 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ADULT; AGED; COMPLICATION; DISEASE FREE SURVIVAL; EPSTEIN BARR VIRUS INFECTION; FEMALE; GENETIC TRANSFECTION; HUMAN; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; NASOPHARYNX TUMOR; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; REAL TIME POLYMERASE CHAIN REACTION; VIROLOGY; WESTERN BLOTTING; YOUNG ADULT;

ADULT; AGED; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL ADHESION MOLECULES; DISEASE-FREE SURVIVAL; EPSTEIN-BARR VIRUS INFECTIONS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; KI-67 ANTIGEN; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; YOUNG ADULT;

EID: 85013076912     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61: 69-90.
2. Gregory CD, Kirchgens C, Edwards CF, Young LS, Rowe M, Forster A, Rabbitts TH and Rickinson AB. Epstein-Barr virus-transformed human precursor B cell lines: altered growth phenotype of lines with germ-line or rearranged but nonexpressed heavy chain genes. Eur J Immunol 1987; 17: 1199-1207.
3. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G, Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290-1295.
4. Szala S, Froehlich M, Scollon M, Kasai Y, Steplewski Z, Koprowski H and Linnenbach AJ. Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci U S A 1990; 87: 3542-3546.
5. Muhlmann G, Spizzo G, Gostner J, Zitt M, Maier H, Moser P, Gastl G, Zitt M, Muller HM, Margreiter R, Ofner D and Fong D. TROP2 expression as prognostic marker for gastric carcinoma. J Clin Pathol 2009; 62: 152-158.
6. Ohmachi T, Tanaka F, Mimori K, Inoue H, Yanaga K and Mori M. Clinical significance of TROP2 expression in colorectal cancer. Clin Cancer Res 2006; 12: 3057-3063.
7. Liu T, Liu Y, Bao X, Tian J, Liu Y and Yang X. Overexpression of TROP2 predicts poor prognosis of patients with cervical cancer and promotes the proliferation and invasion of cervical cancer cells by regulating ERK signaling pathway. PLoS One 2013; 8: e75864.
8. Fong D, Spizzo G, Gostner JM, Gastl G, Moser P, Krammel C, Gerhard S, Rasse M and Laimer K. TROP2: a novel prognostic marker in squamous cell carcinoma of the oral cavity. Mod Pathol 2008; 21: 186-191.
9. Wu H, Xu H, Zhang S, Wang X, Zhu H, Zhang H, Zhu J and Huang J. Potential therapeutic target and independent prognostic marker of TROP2 in laryngeal squamous cell carcinoma. Head Neck 2013; 35: 1373-1378.
10. Fong D, Moser P, Krammel C, Gostner JM, Margreiter R, Mitterer M, Gastl G and Spizzo G. High expression of TROP2 correlates with poor prognosis in pancreatic cancer. Br J Cancer 2008; 99: 1290-1295.
11. Fornaro M, Dell'Arciprete R, Stella M, Bucci C, Nutini M, Capri MG and Alberti S. Cloning of the gene encoding Trop-2, a cell-surface glycoprotein expressed by human carcinomas. Int J Cancer 1995; 62: 610-618.
12. Stoyanova T, Goldstein AS, Cai H, Drake JM, Huang J and Witte ON. Regulated proteolysis of Trop2 drives epithelial hyperplasia and stem cell self-renewal via beta-catenin signaling. Genes Dev 2012; 26: 2271-2285.
13. Guan G, Zhang D, Zheng Y, Wen L, Yu D, Lu Y and Zhao Y. microRNA-423-3p promotes tumor progression via modulation of AdipoR2 in laryngeal carcinoma. Int J Clin Exp Pathol 2014; 7: 5683-5691.
14. Kwok H, Wu CW, Palser AL, Kellam P, Sham PC, Kwong DL and Chiang AK. Genomic diversity of Epstein-Barr virus genomes isolated from primary nasopharyngeal carcinoma biopsy samples. J Virol 2014; 88: 10662-10672.
15. Wanger TM, Dewitt S, Collins A, Maitland NJ, Poghosyan Z and Knauper V. Differential regulation of TROP2 release by PKC isoforms through vesicles and ADAM17. Cell Signal 2015; 27: 1325-1335.
16. Ripani E, Sacchetti A, Corda D and Alberti S. Human Trop-2 is a tumor-associated calcium signal transducer. Int J Cancer 1998; 76: 671-676.
17. Guerra E, Trerotola M, Aloisi AL, Tripaldi R, Vacca G, La Sorda R, Lattanzio R, Piantelli M and Alberti S. The Trop-2 signalling network in cancer growth. Oncogene 2013; 32: 1594-1600.
18. Maetzel D, Denzel S, Mack B, Canis M, Went P, Benk M, Kieu C, Papior P, Baeuerle PA, Munz M and Gires O. Nuclear signalling by tumour-associated antigen EpCAM. Nat Cell Biol 2009; 11: 162-171.
19. Lin JC, Wu YY, Wu JY, Lin TC, Wu CT, Chang YL, Jou YS, Hong TM and Yang PC. TROP2 is epigenetically inactivated and modulates IGF-1R signalling in lung adenocarcinoma. EMBO Mol Med 2012; 4: 472-485.
20. Guerra E, Trerotola M, Dell'Arciprete R, Bonasera V, Palombo B, El-Sewedy T, Ciccimarra T, Crescenzi C, Lorenzini F, Rossi C, Vacca G, Lattanzio R, Piantelli M and Alberti S. A bicistronic CYCLIN D1-TROP2 mRNA chimera demonstrates a novel oncogenic mechanism in human cancer. Cancer Res 2008; 68: 8113-8121.
21. Cubas R, Zhang S, Li M, Chen C and Yao Q. Trop2 expression contributes to tumor pathogenesis by activating the ERK MAPK pathway. Mol Cancer 2010; 9: 253.
22. Goldstein AS, Lawson DA, Cheng D, Sun W, Garraway IP and Witte ON. Trop2 identifies a subpopulation of murine and human prostate basal cells with stem cell characteristics. Proc Natl Acad Sci U S A 2008; 105: 20882-20887.
23. McDougall AR, Tolcos M, Hooper SB, Cole TJ and Wallace MJ. Trop2: from development to disease. Dev Dyn 2015; 244: 99-109.
24. Cardillo TM, Govindan SV, Sharkey RM, Trisal P and Goldenberg DM. Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys. Clin Cancer Res 2011; 17: 3157-3169.
25. Tsao SW, Tsang CM, To KF and Lo KW. The role of Epstein-Barr virus in epithelial malignancies. J Pathol 2015; 235: 323-333.
26. Lo S, Ho WK and Wei WI. Outcome of patients with positive Epstein-Barr virus serologic status in the absence of nasopharyngeal carcinoma in Hong Kong. Arch Otolaryngol Head Neck Surg 2004; 130: 770-772.
27. Ma SD, Yu X, Mertz JE, Gumperz JE, Reinheim E, Zhou Y, Tang W, Burlingham WJ, Gulley ML and Kenney SC. An Epstein-Barr Virus (EBV) mutant with enhanced BZLF1 expression causes lymphomas with abortive lytic EBV infection in a humanized mouse model. J Virol 2012; 86: 7976-7987.
28. Tsang CM, Zhang G, Seto E, Takada K, Deng W, Yip YL, Man C, Hau PM, Chen H, Cao Y, Lo KW, Middeldorp JM, Cheung AL and Tsao SW. Epstein-Barr virus infection in immortalized nasopharyngeal epithelial cells: regulation of infection and phenotypic characterization. Int J Cancer 2010; 127: 1570-1583.